BR9812139A - Vacina - Google Patents

Vacina

Info

Publication number
BR9812139A
BR9812139A BR9812139-1A BR9812139A BR9812139A BR 9812139 A BR9812139 A BR 9812139A BR 9812139 A BR9812139 A BR 9812139A BR 9812139 A BR9812139 A BR 9812139A
Authority
BR
Brazil
Prior art keywords
hpv
vaccine
provides
prophylaxis
linked
Prior art date
Application number
BR9812139-1A
Other languages
English (en)
Inventor
Claudine Bruck
Teresa Cabezon Silva
Anne-Marie Eva Fernand Delisse
Catherine Marie Ghislai Gerard
Angela Lombardo-Bencheikh
Original Assignee
Smithkline Beecham Biolog
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Biolog filed Critical Smithkline Beecham Biolog
Publication of BR9812139A publication Critical patent/BR9812139A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

Patente de Invenção:<B>"VACINA"<D>. A patente de invenção proporciona proteínas de fusão do vírus do papiloma humano (HPV), ligadas a um parceiro de fusão imunológica que proporciona epítopos T auxiliares ao antígeno de HPV. São providas formulações de vacina que são úteis no tratamento ou profilaxia de lesões induzidas por HPV.
BR9812139-1A 1997-08-22 1998-08-17 Vacina BR9812139A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9717953.5A GB9717953D0 (en) 1997-08-22 1997-08-22 Vaccine
PCT/EP1998/005285 WO1999010375A2 (en) 1997-08-22 1998-08-17 Vaccine against hpv

Publications (1)

Publication Number Publication Date
BR9812139A true BR9812139A (pt) 2000-07-18

Family

ID=10817971

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9812139-1A BR9812139A (pt) 1997-08-22 1998-08-17 Vacina

Country Status (23)

Country Link
US (2) US6342224B1 (pt)
EP (1) EP1007551B1 (pt)
JP (1) JP2001513986A (pt)
KR (1) KR20010023193A (pt)
CN (1) CN1276833A (pt)
AT (1) ATE267211T1 (pt)
AU (1) AU732946B2 (pt)
BR (1) BR9812139A (pt)
CA (1) CA2301920C (pt)
CO (1) CO4810234A1 (pt)
DE (1) DE69824013T2 (pt)
ES (1) ES2221198T3 (pt)
GB (1) GB9717953D0 (pt)
HU (1) HUP0004327A3 (pt)
IL (1) IL134392A0 (pt)
MA (1) MA24638A1 (pt)
NO (1) NO20000850L (pt)
NZ (1) NZ502632A (pt)
PL (1) PL339009A1 (pt)
TR (1) TR200000480T2 (pt)
UY (1) UY25146A1 (pt)
WO (1) WO1999010375A2 (pt)
ZA (1) ZA987591B (pt)

Families Citing this family (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9706957D0 (en) 1997-04-05 1997-05-21 Smithkline Beecham Plc Formulation
EP1025217B1 (en) * 1997-10-24 2006-10-04 Invitrogen Corporation Recombinational cloning using nucleic acids having recombination sites
GB9820525D0 (en) 1998-09-21 1998-11-11 Allergy Therapeutics Ltd Formulation
SI1117421T1 (en) * 1998-10-05 2004-12-31 Pharamexa A/S Methods for therapeutic vaccination
DE69918146T2 (de) 1998-10-05 2005-07-07 Pharmexa A/S Verfahren zur therapeutischen impfung
EP1126876B1 (en) 1998-10-16 2007-03-21 GlaxoSmithKline Biologicals S.A. Adjuvant systems and vaccines
CA2767116A1 (en) * 1999-05-13 2000-11-23 Wyeth Holdings Corporation Adjuvant combination formulations
GB9921146D0 (en) * 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
GB0000891D0 (en) 2000-01-14 2000-03-08 Allergy Therapeutics Ltd Formulation
US7015033B1 (en) * 2000-05-25 2006-03-21 Aventis Pasteur Limited Co-expression of recombination proteins
AU2001272491A1 (en) * 2000-06-26 2002-01-08 Smithkline Beecham Biologicals (S.A.) Triple fusion proteins comprising ubiquitin fused between thioredoxin and a polypeptide of interest
US7198924B2 (en) 2000-12-11 2007-04-03 Invitrogen Corporation Methods and compositions for synthesis of nucleic acid molecules using multiple recognition sites
DE60126737T2 (de) * 2001-03-23 2007-11-08 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Modifizierte HPV E6- und E7-Gene und -Proteine als Impfstoff
JP2005516897A (ja) * 2001-11-07 2005-06-09 イネックス ファーマシューティカルズ コーポレイション 改善された粘膜のワクチン及びその使用方法
US6861410B1 (en) * 2002-03-21 2005-03-01 Chiron Corporation Immunological adjuvant compositions
FR2839072A1 (fr) * 2002-04-24 2003-10-31 Neovacs Produit d'expression d'un adn codant une proteine e7 mutee de hpv-16, composition immunogene contenant ledit produit d'expression et son procede de preparation
FR2839080B1 (fr) * 2003-04-03 2007-09-28 Neovacs Procede de preparation d'un produit d'expression d'un adn codant une proteine e7 mutee de hpv-16, par des cellules de la levure pichia pastoris
US20040013649A1 (en) * 2002-05-10 2004-01-22 Inex Pharmaceuticals Corporation Cancer vaccines and methods of using the same
US20040009944A1 (en) * 2002-05-10 2004-01-15 Inex Pharmaceuticals Corporation Methylated immunostimulatory oligonucleotides and methods of using the same
AU2003253992A1 (en) * 2002-07-18 2004-02-09 Robert P. Bennett Viral vectors containing recombination sites
KR101239242B1 (ko) 2002-08-02 2013-03-11 글락소스미스클라인 바이오로지칼즈 에스.에이. 항원 조합물을 포함하는 나이세리아 백신 조성물
US20060147417A1 (en) * 2002-08-30 2006-07-06 Claire Ashman Immunogenic composition comprising an il-13 element and t cell epitopes, and its therapeutic use
DK1553966T3 (da) * 2002-10-03 2012-09-17 Wyeth Corp Fusionspeptider omfattende human papillomavirus E7- og E6- polypeptider samt immunogene sammensætninger deraf
US8409587B2 (en) 2002-11-01 2013-04-02 Glaxosmithkline Biologicals S.A. Immunogenic composition
TWI315986B (en) * 2002-11-07 2009-10-21 Synergy America Inc Compositions and methods for treating or preventing pneumococcal infection
EP1608767B1 (en) * 2003-03-24 2012-02-22 Merck Sharp & Dohme Corp. Optimized expression of hpv 31 l1 in yeast
CZ297389B6 (cs) * 2003-07-03 2006-11-15 Ústav Molekulární Biologie Rostlin Av Cr Fúzní protein pro vakcinaci proti lidskému papillomaviru a zpusob jeho produkce
EP1667712B1 (en) 2003-10-02 2010-07-21 GlaxoSmithKline Biologicals S.A. B. pertussis antigens and use thereof in vaccination
JP2007512838A (ja) 2003-12-01 2007-05-24 インヴィトロジェン コーポレーション 組換え部位を含む核酸分子およびその使用方法
WO2005089164A2 (en) * 2003-12-31 2005-09-29 Pharmexa Inc. Inducing cellular immune responses to human papillomavirus using peptide and nucleic acid compositions
US10941353B2 (en) * 2004-04-28 2021-03-09 Hydrocarbon Technology & Innovation, Llc Methods and mixing systems for introducing catalyst precursor into heavy oil feedstock
EP1753845B1 (en) * 2004-04-28 2018-01-03 Headwaters Heavy Oil, LLC Fixed bed hydroprocessing methods and systems and methods for upgrading an existing fixed bed system
CA2564346C (en) 2004-04-28 2016-03-22 Headwaters Heavy Oil, Llc Ebullated bed hydroprocessing methods and systems and methods of upgrading an existing ebullated bed system
GB0427131D0 (en) * 2004-12-10 2005-01-12 Glaxosmithkline Biolog Sa Novel combination
GB0505996D0 (en) 2005-03-23 2005-04-27 Glaxosmithkline Biolog Sa Fermentation process
US8329184B2 (en) 2005-06-27 2012-12-11 Glaxosmithkline Biologicals S.A. Process for manufacturing vaccines
US7732166B2 (en) * 2005-11-15 2010-06-08 Oncohealth Corporation Detection method for human pappilomavirus (HPV) and its application in cervical cancer
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
EP2049559B1 (en) * 2006-07-28 2012-12-19 The Trustees of the University of Pennsylvania Improved hpv vaccines
PE20080913A1 (es) * 2006-09-08 2008-08-21 Wyeth Corp Lavado de arginina en la purificacion de proteinas usando cromatografia de afinidad
BRPI0716959A2 (pt) 2006-09-26 2013-10-29 Infectious Disease Res Inst Composição de vacina contendo adjuvante sintético
EP2086582B1 (en) 2006-10-12 2012-11-14 GlaxoSmithKline Biologicals s.a. Vaccine comprising an oil in water emulsion adjuvant
WO2008043774A1 (en) 2006-10-12 2008-04-17 Glaxosmithkline Biologicals S.A. Vaccine comprising an oil in water emulsion adjuvant
US8916342B2 (en) 2006-11-13 2014-12-23 Oncohealth Corp. Identification of high grade or ≧ CIN2 for early stages and late stages detection, screening, and diagnosis of human papillomavirus (HPV) and HPV-associated cancers
US20100003704A1 (en) 2008-06-13 2010-01-07 Shuling Cheng IN SITU detection of early stages and late stages HPV infection
US8968995B2 (en) 2008-11-12 2015-03-03 Oncohealth Corp. Detection, screening, and diagnosis of HPV-associated cancers
ES2393812T3 (es) * 2007-01-15 2012-12-28 Glaxosmithkline Biologicals Sa Vacuna
US8034232B2 (en) * 2007-10-31 2011-10-11 Headwaters Technology Innovation, Llc Methods for increasing catalyst concentration in heavy oil and/or coal resid hydrocracker
US8426163B2 (en) 2007-12-07 2013-04-23 National Health Research Institutes Production of lipidated proteins in E. coli
US8466259B2 (en) 2007-12-07 2013-06-18 National Health Research Institutes Adjuvants
US8142645B2 (en) * 2008-01-03 2012-03-27 Headwaters Technology Innovation, Llc Process for increasing the mono-aromatic content of polynuclear-aromatic-containing feedstocks
MX337723B (es) 2008-12-09 2016-03-15 Pfizer Vaccines Llc Vacuna de peptido ch3 de ige.
CA2653478A1 (en) * 2009-01-23 2010-07-23 Gregg Martin Automated wash system for industrial vehicles
US8287880B2 (en) 2009-06-02 2012-10-16 National Health Research Institutes Lipidated vaccine against dengue virus infection
EP3124491B1 (en) 2009-06-05 2019-10-30 Infectious Disease Research Institute Synthetic glucopyranosyl lipid adjuvants and vaccine compositions as well as pharmaceutical compositions containing them
CN102482327B (zh) * 2009-06-22 2014-10-29 财团法人卫生研究院 脂质化肿瘤相关抗原及其免疫治疗的组成物及方法
IN2012DN00446A (pt) 2009-07-30 2015-05-15 Pfizer Vaccines Llc
AR074485A1 (es) * 2009-12-04 2011-01-19 Consejo Nac Invest Cient Tec Vacuna contra lesiones neoplasicas o cancerosas causadas por el virus del papiloma humano (vph), procedimientos, usos y metodos
EP2521914A4 (en) 2010-01-08 2013-07-10 Oncohealth Corp CELL-BASED HPV IMMUNOTESTS HAVE A HIGH PERFORMANCE FOR DIAGNOSIS AND SCANNING OF HPV ASSOCIATED CANCER
CA2792683A1 (en) 2010-03-10 2011-09-15 Glaxosmithkline Biologicals S.A. Neisserial fhbp vaccine composition
EP2575868A1 (en) 2010-06-07 2013-04-10 Pfizer Vaccines LLC Ige ch3 peptide vaccine
PL2604629T3 (pl) * 2010-08-13 2018-08-31 Genexine, Inc. Kompozycja do zapobiegania lub leczenia raka szyjki macicy ze wzmacniaczem odporności przeciwko wirusowi brodawczaka ludzkiego
GB201015132D0 (en) 2010-09-10 2010-10-27 Univ Bristol Vaccine composition
TW201221642A (en) 2010-11-15 2012-06-01 Nat Health Research Institutes Method of producing lipidated polypeptides
TWI507413B (zh) 2010-11-15 2015-11-11 Nat Health Research Institutes 脂質化多抗原表位疫苗
EP3632463A1 (en) 2011-04-08 2020-04-08 Immune Design Corp. Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
US9790440B2 (en) 2011-09-23 2017-10-17 Headwaters Technology Innovation Group, Inc. Methods for increasing catalyst concentration in heavy oil and/or coal resid hydrocracker
WO2013112549A1 (en) * 2012-01-24 2013-08-01 Sanford Research/USD Polynucleotides for treating oncogenic viral polypeptide positive tumors
PL2811981T3 (pl) 2012-02-07 2019-09-30 Infectious Disease Research Institute Ulepszone formulacje adiuwantowe zawierające agonistę TLR4 oraz sposoby ich zastosowania
NZ701881A (en) 2012-05-16 2016-10-28 Immune Design Corp Vaccines for hsv-2
US9644157B2 (en) 2012-07-30 2017-05-09 Headwaters Heavy Oil, Llc Methods and systems for upgrading heavy oil using catalytic hydrocracking and thermal coking
EP3586870A1 (en) 2013-03-12 2020-01-01 The Trustees Of The University Of Pennsylvania Improved vaccines for human papilloma virus and methods for using the same
MX370573B (es) 2013-04-18 2019-12-17 Immune Design Corp Monoterapia con glucopiranosil lipido a para usarse en el tratamiento del cancer.
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
EP3915579A1 (en) 2013-12-31 2021-12-01 Infectious Disease Research Institute Single vial vaccine formulations
CN103772508B (zh) * 2014-01-15 2017-05-10 深圳泰来生物医药有限公司 免疫增强的人乳头瘤病毒感染及相关疾病的治疗性疫苗
KR102523984B1 (ko) 2014-08-15 2023-04-20 주식회사 제넥신 자궁경부 종양의 치료 방법
WO2016069774A1 (en) * 2014-10-28 2016-05-06 Agrivida, Inc. Methods and compositions for stabilizing trans-splicing intein modified proteases
WO2016090540A1 (zh) * 2014-12-08 2016-06-16 刘日廷 人乳头瘤病毒(hpv)18型致癌性e6和e7蛋白的抗原表位最小基序肽
JP5973007B2 (ja) * 2015-01-30 2016-08-17 ジェネクサイン・インコーポレーテッド ヒトパピローマウイルス変形体及び免疫増強剤を含む子宮頸癌の予防または治療用組成物
US11414608B2 (en) 2015-09-22 2022-08-16 Hydrocarbon Technology & Innovation, Llc Upgraded ebullated bed reactor used with opportunity feedstocks
US11414607B2 (en) 2015-09-22 2022-08-16 Hydrocarbon Technology & Innovation, Llc Upgraded ebullated bed reactor with increased production rate of converted products
TWI670280B (zh) * 2016-02-23 2019-09-01 財團法人國家衛生研究院 人類乳突病毒之脂質抗原及用於人類乳突病毒相關疾病之免疫治療組合物
JP7195147B2 (ja) 2016-05-16 2022-12-23 アクセス ツー アドバンスト ヘルス インスティチュート Ｐｅｇ化リポソームおよび使用方法
US11421164B2 (en) 2016-06-08 2022-08-23 Hydrocarbon Technology & Innovation, Llc Dual catalyst system for ebullated bed upgrading to produce improved quality vacuum residue product
MX2018002577A (es) 2017-03-02 2018-11-09 Hydrocarbon Tech & Innovation Llc Reactor de lecho en ebullicion mejorado con menos sedimento de ensuciamiento.
US11732203B2 (en) 2017-03-02 2023-08-22 Hydrocarbon Technology & Innovation, Llc Ebullated bed reactor upgraded to produce sediment that causes less equipment fouling
JP2020524143A (ja) 2017-06-15 2020-08-13 インフェクシャス ディズィーズ リサーチ インスティチュート ナノ構造脂質担体、安定エマルジョン、およびその使用
CA3057131C (en) 2018-10-17 2024-04-23 Hydrocarbon Technology And Innovation, Llc Upgraded ebullated bed reactor with no recycle buildup of asphaltenes in vacuum bottoms
KR20220109444A (ko) 2020-04-24 2022-08-04 주식회사 제넥신 자궁경부암 치료방법

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2586428B1 (fr) * 1985-08-26 1988-11-25 Pasteur Institut Polypeptides et anticorps, caracteristiques du papillomavirus et leurs applications au diagnostic in vitro, a la prevention et/ou la lutte contre des infections a papillomavirus
DE3907721A1 (de) * 1989-03-10 1990-09-20 Behringwerke Ag Immunogene regionen auf dem e7-protein des humanen papillomvierus typ 16
DE4015044A1 (de) 1990-05-10 1991-11-14 Behringwerke Ag Seroreaktive epitope auf proteinen des menschlichen papillomavirus (hpv) 18
AU8762991A (en) * 1990-09-26 1992-04-15 Bristol-Myers Squibb Company Human papilloma viral protein expression for use in vaccine compositions
IL105554A (en) * 1992-05-05 1999-08-17 Univ Leiden Peptides of human papillomavirus for use in preparations elicit a human T cell response
US5869445A (en) * 1993-03-17 1999-02-09 University Of Washington Methods for eliciting or enhancing reactivity to HER-2/neu protein
DE4441197C1 (de) * 1994-11-18 1996-03-28 Deutsches Krebsforsch Expressionsplasmide für Hefe
AUPN015794A0 (en) * 1994-12-20 1995-01-19 Csl Limited Variants of human papilloma virus antigens
JP3958360B2 (ja) * 1995-02-24 2007-08-15 キャンタブ ファーマシューティカルズ リサーチ リミティド 免疫治療剤として役立つポリペプチド及びポリペプチド調製の方法
US5843752A (en) * 1995-05-12 1998-12-01 Schering Corporation Soluble active hepatitis C virus protease
US6224870B1 (en) * 1997-01-24 2001-05-01 Genitrix, Ltd. Vaccine compositions and methods of modulating immune responses
US5958750A (en) * 1996-07-03 1999-09-28 Inctye Pharmaceuticals, Inc. Human hyaluronidase

Also Published As

Publication number Publication date
ZA987591B (en) 2000-02-21
EP1007551A2 (en) 2000-06-14
AU732946B2 (en) 2001-05-03
DE69824013D1 (de) 2004-06-24
NO20000850D0 (no) 2000-02-21
JP2001513986A (ja) 2001-09-11
HUP0004327A3 (en) 2003-08-28
CO4810234A1 (es) 1999-06-30
ATE267211T1 (de) 2004-06-15
UY25146A1 (es) 2000-12-29
TR200000480T2 (tr) 2000-07-21
WO1999010375A3 (en) 1999-06-10
IL134392A0 (en) 2001-04-30
EP1007551B1 (en) 2004-05-19
AU9263998A (en) 1999-03-16
NZ502632A (en) 2002-03-28
US20020182221A1 (en) 2002-12-05
KR20010023193A (ko) 2001-03-26
CA2301920A1 (en) 1999-03-04
CN1276833A (zh) 2000-12-13
WO1999010375A2 (en) 1999-03-04
CA2301920C (en) 2011-01-04
GB9717953D0 (en) 1997-10-29
MA24638A1 (fr) 1999-04-01
HUP0004327A1 (en) 2001-03-28
DE69824013T2 (de) 2005-06-02
US6342224B1 (en) 2002-01-29
NO20000850L (no) 2000-04-14
PL339009A1 (en) 2000-12-04
ES2221198T3 (es) 2004-12-16

Similar Documents

Publication Publication Date Title
BR9812139A (pt) Vacina
BR9814487A (pt) &#34;vacina&#34;
MXPA02005639A (es) Induccion de respuestas celulares iinmunologicas al virus de papiloma humano y utilizacion de composiciones de peptidos y acidos nucleico.
HUP0301308A2 (hu) Emberi Papillomavírus-fertőzés gyógykezelése
IL134341A0 (en) Compositions for inducing an immune response containing an hpv protein antigen
DE69936784D1 (de) Behandlung von gebärmutterhalskrebs
PE20040554A1 (es) Vacunas que comprenden proteinas de fusion
IL140217A0 (en) Particles of hcv envelope proteins: use for vaccination
UA85536C2 (en) Viral antigens
DE69840383D1 (de) Ctl epitope des epstein-barr virus
ATE245164T1 (de) Rekombinanter papillomavirus l1
WO2000018351A3 (en) Aglyco products and methods of use
CA2042236A1 (en) Seroreactive epitopes on proteins of human papillomavirus (hpv) 18
WO2002068654A3 (es) Poxvirus recombinantes para proteinas quimericas del virus de la inmunodeficiencia humana
CA2295316A1 (en) Homogeneous human papilloma virus capsomere containing compositions, methods for manufacture, and the use thereof as diagnostic, prophylactic or therapy
WO2002070004A3 (en) Papillomavirus vaccines
HUP0003511A2 (hu) Hepatitisz-B-vírus polipeptidek
BR9905780A (pt) Antìgenos vacinais de leptospira para prevenção da laptospirose
ECSP982629A (es) Proteinas de fusion, proteina que proporciona epitopos auxiliares de t un antigeno de virus de papiloma humano
AP1638A (en) Peptide mimics of conserved gonococcal epitopes and methods and compositions using them.
ES2105984A1 (es) Adenovirus recombinantes que expresan antigenos del virus de la gastroenteritis porcina transmisible (vgpt) y su empleo en la formacion de vacunas.
RU2001127050A (ru) Штамм вируса Эбола &#34;Заир К-5&#34; для проведения модельных экспериментов и приготовления диагностических и вакцинных препаратов

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1890 DE 27/03/2007.